Project Details
Description
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
| Status | Active |
|---|---|
| Effective start/end date | 4/23/20 → 4/30/25 |
Funding
- MERSANA THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.